Monday, April 29, 2019

10:00 AM - 8:00 PM
Exhibit Hall Set-up (Exhibitors Only)

10:00 AM - 7:00 PM
Registration Open

11:00 AM Sign-in and Lunch • 11:30 AM - 1:00 PM
CE: Analyzing the Impact of Specialty Pharmacy Services on Outcomes in Pulmonary Arterial Hypertension
Speakers: Matthew Casciano and Chris Ogurchak
Pulmonary arterial hypertension (PAH) is a rare progressive disorder that is characterized by hypertension in the arteries of the lungs. The exact cause of PAH is unknown, and there is no cure for the disease. Treatment goals for PAH are focused on symptom management. Treatment for PAH has advanced significantly due to the introduction of PAH-targeted drug therapy. Therapy goals for patients with PAH include improvement in exercise capacity, improvement in quality of life, and decreased mortality risk. Focused care provided by specialty pharmacists can dramatically improve the adherence and outcomes of patients with PAH to optimize their quality of life.

11:00 AM Sign-in and Lunch • 11:30 AM - 1:00 PM
CE: Specialty Pharmacy Care and Cost Management Strategies for Psoriatic Disease Therapies
Speakers: Alan Menter, Robin Dore and Michael Zeglinski
Psoriasis and psoriatic arthritis presents a significant clinical and humanistic burden to patients and payers. Fortunately, there has been a marked increase in the number of safe and effective therapies for the disease. As a result, payers, specialty pharmacists, and affiliated providers are challenged to match patients with the most appropriate therapeutic option. This program will focus on the therapeutic options available to manage the spectrum of pathologic challenges confronted by patients with psoriatic disease which can help enable specialty pharmacy professionals to improve patient quality of life and clinical outcomes.
Monday, April 29, 2019

1:00 PM - 2:30 PM

NCPDP Specialty Sessions: Leveraging Standards for Improved Outcomes

Session 1
How NCPDP is Improving Speed to Specialty Therapy
Speakers: Pooja Babbrah and John Hill
For 40+ years, NCPDP has led the pharmacy industry’s transformation from paper and fax by creating and promoting standards for real-time electronic healthcare transactions. Now, NCPDP has moved to the forefront of automating specialty pharmacy through the creation of a new Specialty Pharmacy Work Group. This session will detail the contributions that NCPDP has made to specialty pharmacy and highlight opportunities for attendees to participate in leading an industry-transforming effort to enhance speed-to-therapy, reduce time and costs of managing specialty medications and help ensure patients’ access and adherence to prescribed therapies. This session will provide attendees with a general overview of NCPDP and the topics being covered within NCPDP’s Work Group 18 Specialty Pharmacy and will cover the initiatives underway to automate manual processes and transactions to support specialty management.

Session 2
Real-Time Benefit Check: The Next Revolution in Healthcare
Speakers: Jill Helm and Julie Hessick
Real-time benefit check (RTBC) is the next revolution coming to healthcare. RTBC leverages NCPDP standards to provide accurate, patient-specific information on benefit coverage and medication options and related out-of-pocket (OOP) costs at the point of prescribing. This session will examine how RTBC may help reduce medication abandonment, improve medication adherence and outcomes and enhance patient and provider satisfaction.

Session 3
In Workflow Best Practices for Automating REMS
Speakers: Pooja Babbrah, Shivani Patel and Mark Sasala
In 2011, NCPDP released its implementation guide for REMS Transactions for the Telecommunication Standard. The standard is used to process claims; the change allows pharmacies to electronically confirm that REMS requirements have been met and the pharmacy can dispense the medication. In addition, the new version of SCRIPT allows for REMS administrators to present prescribers with a “question set” to submit required REMS information electronically. This session will examine the new REMS transactions and provide information on best practices for implementation.
Monday, April 29, 2019

1:30 PM Sign-in • 2:00 PM - 3:30 PM

**CE: Analyzing Hereditary Angioedema: A Review of Evidence and Treatment Approaches**

Speakers: Mark Malesker and Cari Pao

Hereditary angioedema (HAE) is a rare and serious disease affecting approximately 1 in 50,000 people worldwide. Recent data indicate that patients may be undiagnosed for over 10 years after the onset of disease. Despite the introduction of several novel treatments for HAE over the past few years, HAE still results in significant physical, psychosocial, and economic burden to patients and society. Treatments that target the mediatory pathways (C1-INH, kallikrein, and bradykinin) have been FDA approved for use as either treatment for acute attacks or as prophylaxis. With the growing number of costly agents, it is essential for specialty pharmacists to be aware of emerging data. It is imperative that those involved with formulary and/or the management of patients with HAE are aware of both clinical and cost data in order to improve patient care and quality of life.

1:30 PM Sign-in • 2:00 PM - 3:30 PM

**CE: Managing Multiple Sclerosis: A Guide for Specialty Pharmacy Professionals**

Speakers: Harold Moses and Ed Pezalla

Despite the availability of more than a dozen disease modifying treatments (DMTs), health care resource utilization associated with multiple sclerosis (MS) is significant and continues to rise. The continually evolving MS treatment landscape accentuates the need for increased disease and therapeutic knowledge amongst managed care and specialty pharmacy professionals in order to optimize clinical outcomes, reduce treatment variability, and increase patient engagement in their own care. The expert faculty panel will discuss best practices to deliver quality care to MS patients and improve quality of life over the course of the disease.

3:00 PM - 4:30 PM

**All Together: A Women’s Leadership Forum**

**Welcome and Introductions**

Speaker: Suzette DiMascio

**What it Mean to be a Pharmacist and a Mom in the 21st Century**

Speaker: Suzanne Soliman

**A Business Priority: How a Culture of Equality Drives Innovation**

Speaker: Keena Patel

As of April 19, 2019. Agenda is subject to change.
Monday, April 29, 2019

4:00 PM Sign-in • 4:30 PM - 6:00 PM

Lafleur

**CE: Examining Therapy, Health Care Utilization, and Patient Management for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)**

Speakers: Amy Clarke and Tuan Vu

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a debilitating and degenerative disease in which extremity nerve damage results in reduced functioning. Approximately 70% to 90% of patients will have symptom improvement with immunoglobulin therapies. The introduction of subcutaneous (SC) immunoglobulin for CIDP treatment has created unique changes to the management of the disease. SC administration has been shown to be as effective as intravenous (IV) administration in maintaining disease stability. Specialty and managed care pharmacy professionals must be able to differentiate the IV and SC therapies available for CIDP management and should understand when it is clinically appropriate to continue or stop therapy. Additionally, health care professionals must familiarize themselves with the intricacies of CIDP patient management, treatment coordination, and their effects on health care utilization and outcomes.

4:00 PM Sign-in • 4:30 PM - 6:00 PM

Margaux 1

**CE: Employing Immuno-Oncology Biomarkers to Guide Treatment Decision Making: Managed Care and Specialty Pharmacist Perspectives**

Speakers: Lisa Davis and Matthew Farber

This presentation will provide pharmacists practicing in managed care and specialty pharmacy settings with education focused on contemporary uses of biomarkers in immuno-oncology treatment decision making and how pharmacists can play a role in many aspects of both drug therapy and formulary management thus leading to improved access to care and outcomes.

5:00 PM - 6:30 PM

Sunset Terrace & Pool

**Welcome Reception**

Connect with key industry professionals while enjoying cocktails and hors d'oeuvres.
Monday, April 29, 2019

6:30 PM Sign-in and Dinner • 7:00 PM - 8:30 PM

**CE: PCSK9 Inhibitors: Managing Hypercholesterolemia and Improving Patient Outcomes**

Speakers: Rhonda Cooper-DeHoff and Joseph Saseen

Statin therapy remains the cornerstone of managing elevated LDL-C; however, overall compliance with statins remains suboptimal, and considerable evidence indicates that low adherence to statins is linked with poorer outcomes. Some patients may benefit from alternative approaches for LDL-C lowering, particularly those with familial hypercholesterolemia, those in whom LDL-C lowering is insufficient, or who are intolerant to statins. In 2015, the FDA approved the first 2 agents in the PCSK9 inhibitor class: alirocumab and evolocumab. As cost is a major factor for use, specialty pharmacists need to understand the potential barriers of PCSK9 inhibitor payer approval for patients meeting the required indications and consider recent evidence demonstrating the effectiveness of this drug class for reducing cardiovascular risk.

6:30 PM Sign-in and Dinner • 7:00 PM - 8:30 PM

**CE: Opening Night Crossfire Discussions on Implications of New Advances in Diabetic Retinopathy**

Speakers: Samit Bhatt, David Boyer and Darius Moshfeghi

Uniquely tailored to address the needs of specialty and managed care pharmacy professionals, this symposium takes a deep dive into new and emerging clinical data that are shaping decision-making for subpopulations of patients with diabetic retinopathy (DR). Case-based discussions set the stage for applied problem-solving related to early identification of at-risk patients with diabetes, appropriate therapy selection, and promoting eye exams and treatment adherence. This program will help specialty and managed care pharmacy professionals apply the latest clinical evidence to decision-making within their organizations.

As of April 19, 2019. Agenda is subject to change.
Tuesday, April 30, 2019

6:30 AM - 7:00 PM
Registration Open

6:30 AM Sign-in and Breakfast • 7:00 AM - 8:30 AM

**CE: Advancing Specialty Pharmacy’s Role in the Multidisciplinary Approach to Managing Inflammatory Bowel Disease**

Speakers: Rolf Benirschke and Christopher Owens

Inflammatory bowel disease (IBD) is compromised Crohn's disease and ulcerative colitis. The advancement of treatment for IBD includes anti–TNF-α medications, integrin inhibitors, adhesion molecules, colony-stimulating factors, and others. Unlike traditional medications that tend to suppress the entire immune system, biologic therapies offer a targeted mechanism of action. It is critical to develop an individualized treatment plan that incorporates earlier use of immunosuppressants and biological therapy to minimize disease progression. Specialty pharmacists can help identify patients who have not responded to conventional therapy and who may benefit from other therapeutic options (ie, biological agents) by utilizing a cost-effective approach to optimize patients’ quality of life.

6:30 AM Sign-in and Breakfast • 7:00 AM - 8:30 AM

**CE: Novel Advances in Hereditary ATTR Amyloidosis: Payer and Specialty Pharmacy Considerations**

Speakers: Sami Khella and Karen Thomas

Amyloidosis refers to a heterogeneous group of multisystemic, debilitating, fatal disorders affecting normal tissue and organ structure and function due to amyloid fibril deposits in extracellular tissues. Hereditary transthyretin amyloidosis (hATTR) is one of these disorders and affects approximately 50,000 individuals worldwide. As the disease progresses, patients experience a myriad of symptoms that may include weight loss, gastrointestinal dysfunction, and polyneuropathy. The course of hATTR may be slowed with early diagnosis and treatment. Until recently, treatments have only helped to alleviate symptoms, but the treatment landscape has changed with the approval of 2 disease-modifying therapies in the United States that target the disease process at the cellular level. Due to its progressive nature, hATTR impacts patients and their caregivers, both of whom report a much reduced quality of life due to the physical, mental, and financial demands of the disease. Specialty pharmacists and payers must be familiar with current and emerging therapies for the treatment of hATTR to improve the clinical outcomes for patients with hATTR while managing health care resources.
Tuesday, April 30, 2019

7:30 AM - 9:30 AM  
Buffet Breakfast  
Latour Ballroom & Sunset Terrace

9:00 AM - 9:30 AM  
Transforming Specialty Pharmacy Operations to Deliver Better Patient Care  
Speakers: James Adams and Sean Creehan  
A core component of success in specialty pharmacy is the ability to leverage data and connectivity to achieve a superior coordination of care experience, as well as meaningful efficiency improvements. This session will describe how cloud-based technology is being leveraged at AllianceRx Walgreens Prime to connect various parts of the healthcare delivery matrix and provide patients living with complex, chronic illnesses with more holistic care and improved outcomes.

9:00 AM - 9:30 AM  
Innovations in Oncology: Specialty Pipeline Update  
Speakers: Cheryl Allen and Florencio Calderon  
Join us for a deep dive into the specialty oncology pipeline to discover key innovations leading pharmaceutical development. We will discuss recent approvals in cell and gene therapy, immuno-oncology and genomic biomarkers as examples cutting edge innovations. We will also review anticipated upcoming approvals that promise to deliver innovations in the continuum of care for specialty oncology patients.

9:00 AM - 9:30 AM  
Specialty Lite: An Evolving Fulfillment Model  
Speakers: Tony Lanzone and Snehal Patel  
What defines a product as specialty? Traditionally, high cost/high touch products were considered specialty, requiring patient & physician services including benefit investigation & PA support, copay assistance, designated pharmacy network fulfillment, and ongoing adherence outreach. The notion of high cost products determining patient/physician support models often led to many drugs routed through the standard retail model, thus foregoing beneficial support models for access and cost savings. In recent years, products representing various therapeutic categories including ophthalmology, dermatology and respiratory, have benefited from select support models and provided manufacturers a better glimpse into the product dynamics in the ever-evolving healthcare system. This presentation will provide an overview of the specialty lite model and focus on specific areas of value for non-traditional specialty lite product fulfillment.
Tuesday, April 30, 2019

9:45 AM - 10:15 AM
**How Pharmacies of Different Practice Models Provide Quality Patient Care**
Speakers: Heather Bonome and Jennifer Richards
As specialty pharmacy evolves, various practice models across different dispensing formats have emerged. Regardless of practice model, accreditation remains the best way for a specialty pharmacy to demonstrate its commitment to quality. In this session, URAC experts will follow the journey of an individual patient to show how pharmacies of variable sizes, dispensing formats and practice models have used different means to demonstrate compliance with the standards and ultimately provide consistent, high quality patient care.

9:45 AM - 10:15 AM
**Advanced Pharma Contracting: The Implications of Ongoing Federal & State Prosecutions & Regulations**
Speakers: Michael Hess, Kirk Hunt and Dan Tardiff
Confused by the increasingly complex arrangements between manufacturers and specialty pharmacies while under the intense scrutiny of regulators? We’ll be reviewing advanced legal concepts (and missteps) in specialty pharmacy contracting and how to apply the requirements to the real world. Join three specialty pharma legal industry veterans as they recap all you need to know in the intricate world of specialty pharma contracting.

9:45 AM - 10:15 AM
**Copay Accumulator Programs: Effective Tool for Managing Costs or Barrier to Patient Access?**
Speaker: Bruce Feinberg
In an attempt to manage high costs, pharmacy benefit managers (PBMs) have assigned many specialty drugs to the highest copayment tier. Pharma companies have responded by offering copay assistance programs to offset a portion of the patient’s out-of-pocket expenses using copay coupons or vouchers. PBMs, in turn, have recently launched “copay accumulator programs,” which seek to limit the impact of manufacturers’ coupons by not counting the value of the coupon toward the patient’s deductible. As result, the industry is now engaged in an intensifying debate about whether these programs help to reduce waste and overall drug spending by discouraging patients from taking expensive brand name drugs unnecessarily, or if they add financial burdens onto patients and potentially reduce adherence rates and diminish outcomes. This session will explore both sides of the debate.

10:00 AM - 12:00 PM
**Exhibits & Networking**
Tuesday, April 30, 2019

10:30 AM - 11:00 AM
Innovative Models in Limited Distribution Drug Networks: Insights for Pharma, Specialty Pharmacies and Payers
Speakers: Chris Creamer and Will Pih
Chris will discuss various distribution models available for limited distribution drugs and how each model impacts pharma, providers and patients.

10:30 AM - 11:00 AM
Market Disintermediation: Mergers, Mega Players and Media Hype
Speaker: Dean Erhardt
In the changing world of healthcare does one evaluate and understand the current market structure? There is a new world emerging with technology providers (i.e. Salesforce, Deloitte, IBM), new payers (i.e. CVS-Aetna, Cigna-ESI, Walmart-Humana) and new participants (i.e. Google, Apple, Amazon). In this session Mr. Erhardt discusses the ongoing market changes and how these might impact the go forward strategies of manufacturers as they look at their marketing and commercialization options.

10:30 AM - 11:00 AM
Personalized Benefit Management in Specialty
Speaker: Steve Cutts
Technology is advancing, giving consumers more access and control over their health care experience and outcomes. The PBM landscape is shifting, creating the need to rethink how care is delivered and managed. To keep up with these evolving needs, it’s essential that PBMs seek new ways to deliver care in specialty. This session will cover personalized benefit management in specialty, along with the rise of consumer engagement, the role of digital therapeutics, and future trends.
Tuesday, April 30, 2019

11:15 AM - 11:45 AM
Evaluating and Comparing Treatment Outcomes in Specialty Care
Speakers: Rich Glicklich and Tom Renshaw
Is it possible to measure specialty care treatment outcomes at scale? How do outcomes compare for hospitals with payer and pharmacy access compared to outcomes in a hospital that has to work with an outside payer and pharmacy? During this session, examine a pilot study that looks to answer this question, utilizing 2+ years of electronic health records (EHR) data from Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS) patients.

- Learn about the outcomes measures used and how they were defined.
- Hear the results from this multi-hospital pilot.
- Learn why RA and MS were chosen for this study and why disease states may matter.
- What does the results mean for manufacturers and plan-sponsors?
- What are the future implications and opportunities?

11:15 AM - 11:45 AM
What it Means to be an Independent Specialty Pharmacy in a Vertically Integrated World
Speaker: Paula Bickley
For those of us in the healthcare industry, we have to accept that our market is changing. What we do now will determine how successful we’ll be in the future. Doing what we’ve been doing won’t work; join us in this session where Paula Bickley from Biologics by McKesson proposes a new approach for pharmacies, payers and PBMs to work together in a way that may result in new benefits for everyone—especially our patients.

11:15 AM - 11:45 AM
A Specialty Pharmacy Pipeline Product Update
Speaker: Ray Tancredi
The Specialty Pharmacy Pipeline Product Update will identify selected specialty drugs in the pipeline and highlight the some approval trends within the top specialty disease states

- Review the promising specialty drugs in Late-Stage Development
  - A look at recent specialty product approvals
  - A review of products in the FDA pipeline
- Describe the trends in orphan drugs that target rare diseases
- A look at the disease categories are experiencing the most product growth in specialty pharmacy
Tuesday, April 30, 2019

11:30 AM Sign-in and Lunch • 12:00 PM - 1:30 PM

**CE: A Virtual Reality View--Moderate-to-Severe Atopic Dermatitis: Long-Term Treatment and Managed Care Issues**

Speakers: Jonathan Silverberg and Geoffrey Wall

This session features an interactive, case-based learning environment. Create your own personalized poster using the VIRTUAL REALITY SETS provided to all attendees for viewing this presentation.

---

11:30 AM Sign-in and Lunch • 12:00 PM - 1:30 PM

**CE: Early Interventions for Treating Influenza: Economic Evaluation in Managed Care Settings**

Speakers: Marilyn Bulloch and Sheldon Rich

Influenza is a highly contagious acute respiratory infection caused by influenza viruses A, B, or C. Vaccinations offer the opportunity of protection against influenza, but the rate of vaccination in the United States is suboptimal. Antiviral medications have proven to be effective for the prevention of influenza and can reduce the severity and duration of the flu when used as treatment. Managed care professionals, including pharmacists, should be aware of the treatments available for the prevention and management of influenza as well as the gravity of related complications, especially in high-risk patient populations. Additionally, they should understand the significance of initiating treatment early with antiviral therapy to prevent or reduce the incidence of flu-related complications.

---

12:00 PM - 1:30 PM

**Buffet Lunch**

---

1:00 PM - 1:30 PM

**DELIVERxING Hope to Patients with Rare Diseases: Improving Orphan/Precision Medicine Channels**

Speaker: Gordon Vanscoy

A look into the 2019 FDA pipeline presents many breakthroughs that are imminent for some of the 90% of rare diseases which have no known treatments. However, medical advancements must be managed appropriately due to significant financial cost to society, the payer, the employer, and patient. Specialty pharmacy is poised to transform and maximize patient outcomes in an efficient/data driven manner. Case example will illustrate a contemporary rare disease treatment and channel strategy approach.
Tuesday, April 30, 2019

1:00 PM - 1:30 PM
**Multiple Sclerosis: New Perspectives on the Patient Journey—2019 Update**
Speaker: Bruce Pyenson
Multiple sclerosis (MS) continues to be a top specialty drug management priority for insurers and pharmacy benefit managers. Recent research using new methodology finds almost double the prevalence than generally reported—almost 1 million cases in the US. We applied this new methodology to 13 years of commercial claims data and report information about cost, disability progression and drug adherence. This material updates our work published in 2017.

1:00 PM - 1:30 PM
**Evolution of VBC: What Have We Learned and Where are We Going**
Speaker: Lisa Carman and Gina Guinasso

1:45 PM - 2:15 PM
**Aligning Marketing, HUBs, Market Access, Distribution and Sales Strategies for Specialty Brands**
Speakers: Greg Leighton and David Robinson
Supporting the patient journey for specialty brands requires the collaboration of key stakeholders to streamline the process for product access. A strategically aligned sales force, market access team, distribution channel, patient support provider, and marketing efforts are critical for support. This session will review key strategies and lessons learned across these different channels to offers core principles, tips, and tools to guide a successful brand strategy.

1:45 PM - 2:15 PM
**Data Rules! Strategies for Leveraging Data and Defining Value Based Care**
Speakers: Kristin Chambers, Elizabeth Forner, Diane Giaquinta and Tom Koenig
As specialty drugs dominate the market, payers and manufacturers develop networks of specialty pharmacies to manage cost and obtain data. Basic reporting is not enough, and value must be defined. Health system specialty pharmacies are uniquely positioned to provide coordinated care, utilizing robust data from multiple sites of care and a patient-centric model. This panel explores data needs from various stakeholders and how this impacts product uptake, access and patient outcomes.
Tuesday, April 30, 2019

2:30 PM - 3:00 PM  
**Streamlining Relationships Between Charitable Foundations & Pharmacies to Maximize Patient Grant Usage**  
Speakers: Stacy Carmona, Melissa Paige, Jeffery Zobell and Krista Zodet  
Attendees will learn how pharmacies work with charitable foundations to ensure patients achieve maximum benefit from their grant. Session will include an overview of services by Kroger Specialty Pharmacy as they relate to copayment assistance and managing patient grants. Panel will also discuss utilization of patient access and advocacy services by UVA Health System and Intermountain CF Pediatric Center and engage the audience in an interactive session to address questions and misconceptions about charitable foundations.

2:30 PM - 3:00 PM  
**Preparing for an Uncertain Future: Managing Drug Spend**  
Speaker: Joseph Coppola and George Van Antwerp  
2018 was one of the biggest years for policy efforts to reduce drug prices and out-of-pocket expenses for patients, and actions have continued into 2019. Prescription drug rebates is one area that has come under scrutiny with proposals to eliminate safe-harbor protections. The elimination of rebates – and other initiatives to address US drug spend -- have the potential to transform access and reimbursement of pharmaceutical products. Hear industry leaders discuss implications of these efforts to US health care stakeholders.

2:30 PM - 3:00 PM  
**Enhancing the Physician and Specialty Pharmacy Relationship**  
Speaker: James Orsini

3:00 PM - 6:00 PM  
**Exhibits & Networking**

6:00 PM - 7:30 PM  
**URAC Pharmacy Program Development Updates + Meet the New CEO**  
Speakers: Heather Bonome and Shawn Griffin  
Join us for an interactive discussion, led by URAC’s Director of Pharmacy Heather Bonome, about upcoming revisions to the Specialty Pharmacy standards and the new Home Infusion Therapy Accreditation program for pharmacies. You’ll get an opportunity to meet URAC’s new President and CEO Shawn Griffin, M.D.
Tuesday, April 30, 2019

6:00 PM Sign-in & Dinner • 6:30 PM - 8:00 PM

**CE: A Tech-Based Open Forum for Specialty Pharmacists on the Rise and Role of Biologics for Asthma**

Speakers: Ryan Atkinson, Nicola Hanania and Diego Maselli

Featuring real-time engagement technology, this accredited symposium offers a refreshing opportunity for specialty pharmacists to take a deep dive into the latest advances that are shaping treatment for patients with moderate-to-severe asthma. Case vignettes provide a springboard for open-forum discussions and expert-panel debates on applications of the latest evidence to therapy selection and medication therapy management.

To enable interaction with the educational content, expert faculty, and peers, each attendee will receive a tablet for the duration of the program. Register early to save your spot!

**Top reasons to attend:**

- Get hot-off-the-press evidence from key asthma conferences, including the AAAAI Annual Meeting
- Hear expert views from renowned asthma and specialty pharmacy faculty
- Apply your learning by making decisions in complex patient scenarios involving persistent asthma and comorbidities

As of April 19, 2019. Agenda is subject to change.
Wednesday, May 1, 2019

6:30 AM - 6:00 PM

Registration Open

6:30 AM Sign-in and Breakfast • 7:00 AM - 8:30 AM

**CE: Examining von Willebrand Disease Treatment and the Role of Specialty Pharmacy Services**

Speaker: Tim Affeldt and Sheh-Li Chen

Von Willebrand disease (VWD) is the most common bleeding disorder, affecting up to 1% of the population worldwide, and is caused by the absence of, reduced amounts of, or defects in von Willebrand factor (VWF). Human plasma-derived VWF concentrates containing varying amounts of VWF multimer distribution and factor VIII (FVIII) content have been available for decades. A recombinant VWF, eliminates the need for human donors, decreases the risk for any infectious transfers, and minimizes the thrombosis risk due to the absence of FVIII. Specialty pharmacists should know how to tailor these therapies for specific patients’ needs. Effective interventions will maximize quality of life, reduce hospitalizations and emergency department visits, optimize health care utilization, and effectively manage bleeding risk and adverse events during disease management.

6:30 AM Sign-in and Breakfast • 7:00 AM - 8:30 AM

**CE: Examining Peanut Allergy Pathophysiology, Immunotherapy Data, and Healthcare Utilization: A Primer for Specialty Pharmacy**

Speaker: Michael Blaiss and Christina Ciaccio

With peanut allergies affecting about 2.5% of children and 1.2% of the U.S. population overall, it is the most common food allergy in children and a leading cause of allergy-related death. Its prevalence has tripled in a decade, and only 20% of children are expected to outgrow their peanut allergy pointing to a continued increase in peanut allergy-related costs to the healthcare system. Rising incidence of anaphylaxis has triggered an increase in healthcare resource utilization such as emergency department visits and a reduction in the quality of life for a growing number of patients. Most of the efforts to move treatment toward proactively addressing peanut allergies using immunotherapy are focused on desensitization. Specialty pharmacists will be involved in the dispensing of treatments for patients with peanut allergies and can advise patients and caregivers about adverse effects and monitor for adverse events that may discourage utilization. Availability of new immunotherapies also opens the opportunity for pharmacy benefit management professionals to play a proactive role in developing drug benefit management strategies that support the identification of patients and appropriate immunotherapies to reduce healthcare resource utilization as well as help patients control their allergies and improve their quality of life.
Wednesday, May 1, 2019

7:30 AM - 9:30 AM
Buffet Breakfast
Latour Ballroom & Sunset Terrace

8:30 AM - 10:00 AM
FEATURED BUSINESS SESSION
Specialty Pharmacy Industry Outlook: What's Next?
Speakers: Adam Fein, Lisa Gill and Doug Long
In this thought-provoking Featured Session, hear from three of the industry's top experts as they update their analysis and outlook on our dynamic industry. Adam, Lisa, and Doug will:
• Explain the key trends reshaping specialty drug channels
• Analyze strategic responses by payers, manufacturers, wholesalers, and pharmacies
• Examine how Wall Street and the financial markets view specialty pharmacy
• Highlight the latest data on the specialty market and its role in the healthcare system
• Discuss the implications and outlook for specialty pharmacy industry participants
Encore Ballroom

10:30 AM - 11:15 AM
GENERAL SESSION KEYNOTE
Scott Gottlieb
23rd Commissioner of the Food & Drug Administration
Encore Ballroom

11:15 AM - 11:45 AM
GENERAL SESSION KEYNOTE
A Conversation with Maria Shriver
Activist & Founder of The Women's Alzheimer's Movement
Encore Ballroom

As of April 19, 2019. Agenda is subject to change.
Wednesday, May 1, 2019

11:30 AM Sign-in and Lunch • 12:00 PM - 1:30 PM

**Beethoven**

**CE: Reviewing Clinical Therapy Advances and Management of Amyotrophic Lateral Sclerosis**

Speakers: Sarah Dehoney and Micaila Ruiz

An estimated 20,000 people in the United States are living with amyotrophic lateral sclerosis (ALS). ALS is a progressive disease in which the motor neurons eventually die. Mortality is usually the result of respiratory failure. Although most patients with ALS die within 3 to 5 years after symptoms first appear, about 20% of patients with ALS will live 5 years, 10% will live 10 years, and about 5% will live 20 years or more. Currently, there is no cure for ALS; however, in the last decade advances have been made that are changing the medical treatment landscape of ALS. As new therapies enter into ALS care, a multitude of health care professionals will need to understand more about the disease, therapies, and the nuances of these therapies within ALS care. Ultimately, pharmacists must be part of the health care team to make decisions on medications and therapies that will improve the patient’s quality of life and slow the disease progression, while helping to navigate access to appropriate therapies and manage costs.

11:30 AM Sign-in and Lunch • 12:00 PM - 1:30 PM

**Lafleur**

**CE: Clinical Updates and Cost Management Strategies in Treating Idiopathic Pulmonary Fibrosis**

Speaker: Lisa Lancaster and Geoffrey Wall

Clinical management of idiopathic pulmonary fibrosis (IPF) is complex. Patients have a poor prognosis, with estimated life expectancies ranging from 3 to 5 years. Evolving knowledge of the pathogenesis of IPF has shown that the disease is linked to a dysregulated wound-healing cascade and fibroproliferation, which has allowed for the development of medications such as nintedanib and pirfenidone with different mechanisms to slow disease progression. As additional data become available, specialty pharmacists must be able recognize the strengths and limitations of new and emerging therapies to make cost-effective and clinically appropriate treatment decisions. Additionally, pharmacists can improve medication adherence by educating patients and caregivers about drug administration and handling, adverse effects, and the potential for drug interactions.

12:00 PM - 1:30 PM

**Latour Ballroom & Sunset Terrace**

**Buffet Lunch**
Wednesday, May 1, 2019

1:00 PM - 1:45 PM
The Impact of Market Consolidation on Specialty Patients and Providers
Speakers: LeeAnn Mengel and Rina Shah
Rina Shah (Walgreens) and LeeAnn Mengel (Baptist MD Anderson Cancer Center) will take a deep dive into how partnerships between healthcare providers impact patients and providers. They will explore how their unique collaboration enhances their ability to work together to provide personalized service to patients, offering the ability to better focus on their treatment.

1:00 PM - 1:45 PM
Trending Policy Impacts on Specialty Drugs
Speakers: Everett Neville and Rita Numerof
The Administration’s recent Blueprint for lowering drug costs, and more recent proposals to adopt reference pricing promises significant impact on specialty drugs. If these proposed changes are adopted, they’ll have implications for market access, formulary management and industry structure itself. Panelists will include representatives from a major PBM and a major hospital system who will discuss the status and the likely impacts the industry can expect, specific changes they have or intend to make.

1:00 PM - 1:45 PM
Value Based-Care Opportunities and Trends for Specialty Therapeutics
Speaker: Bedrick Gadea
The oncology landscape is rapidly changing as providers shift focus to value-based care. Specialty manufacturers and stakeholders must closely monitor and navigate several strong forces that are shaping the future state. This session will review key emerging trends within clinical pathways, digital health, alternative payment programs and biosimilars. We will also discuss best practices of how pharmaceutical and specialty pharmacy companies need to evolve based on these emerging oncology trends.

2:00 PM - 2:45 PM
Cancer Care in America: A Fireside Chat with Biden Cancer Initiative President Greg Simon
Speakers: Greg Simon and Burt Zweigenhaft
Wednesday, May 1, 2019

2:00 PM - 2:45 PM
**Then and Now: Understanding the Trend Lines to 2025 and the Operational Challenges of Today**
Speakers: John Cervione and Bill Roth
Presenters Bill Roth, Founding Partner, and John Cervione, Managing Partner, Blue Fin Group will share their insights on the formation of stand-out trends in the industry that are expected to occur over the next five years. Topics such as the rise of integrated care, challenges with poly-pharmacy, the rise of in-office dispensing and the Health System Pharmacy, ERx and EMR innovations, and new forms of accreditation such as rare disease status will be reviewed. In addition, attendees will hear the most current insights regarding tweener drugs and how to deal with their status in the specialty marketplace, as well as what will come with the rise of technology use and eCommerce, and the blurring lines between traditional retail and specialty pharmacy. Along with the crystal ball vision, practical operational disciplines will be shared to best position companies to react and respond to in today’s current changing market dynamics.

3:00 PM - 6:00 PM
**Exhibits & Networking**
Lafite Ballroom

6:00 PM - 7:30 PM
**Exhibit Hall Breakdown (Exhibitors Only)**
Lafite Ballroom

9:00 PM - 12:00 PM
**Grand Evening Reception**
Badges and wristbands required.
Thursday, May 2, 2019

6:30 AM - 12:00 PM
Registration Open

6:30 AM Sign-in and Breakfast • 7:00 AM - 8:30 AM
CE: Integration of PARP Inhibitors for the Treatment of Ovarian Cancer: Significance for Payers and Specialty Pharmacies
Speakers: Laura Alwan and Jason Bergsbaken
Hereditary ovarian cancers have been linked to the presence of germline mutations in the tumor suppression genes as well as breast cancer type 1 and 2 susceptibility genes (BRCA 1 and BRCA 2). There are multiple approved indications for the use of PARP inhibitors, and their use has been shown to extend progression-free survival in patients. Companion diagnostic tests for the presence of mutated BRCA may help to identify which patients will benefit most from PARP inhibitor therapy. As part of the health care team, pharmacists engage in significant roles from helping to identify which patients may benefit most from PARP inhibitor therapies to communicating with patients about therapy expectations, adherence, and monitoring plans while they are receiving PARP inhibitors.

6:30 AM Sign-in and Breakfast • 7:00 AM - 8:30 AM
CE: Evaluating the Economic and Societal Challenges of Diabetic Retinopathy and Diabetic Macular Edema
Speakers: Eric Cannon and Dan Kiernan
Diabetic macular edema (DME) is a leading cause of vision loss and blindness. Medical costs have been estimated to be about 31% higher over a 1-year period and 29% higher over a 3-year period in Medicare patients with untreated DME compared with unaffected patients with diabetes. Intravitreal antivascular endothelial growth factor inhibitors are recommended to reduce the risk of vision loss. Specialty pharmacists are integral members of a patient’s health care team and have a significant impact on the care and management of patients with DME. Additionally, these health care professionals may be closely involved in formulary design and agent substitution, which may decrease health care utilization and improve clinical outcomes in patients with DME.

8:00 AM - 9:30 AM
Continental Breakfast

8:00 AM - 11:00 AM
Exhibit Hall Breakdown (Exhibitors Only)
<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 AM - 9:30 AM</td>
<td>Encore Ballroom 1-3</td>
<td><strong>Implementing Outcomes Research in Specialty Pharmacy Practice: Your Value Story</strong></td>
<td>Autumn Zuckerman</td>
<td>Outcomes research will drive continued specialty pharmacy growth and recognition. Specialty pharmacies are increasingly held accountable to producing optimal patient and medication outcomes by manufacturers, payers, and their respective institutions. However, most specialty pharmacies are ill-equipped to produce meaningful research with current resources. This session will demonstrate the highly successful development of an outcomes program and the use of outcomes research to illustrate specialty pharmacy value to key stakeholders.</td>
</tr>
<tr>
<td>9:00 AM - 9:30 AM</td>
<td>Margaux 1</td>
<td><strong>Patient Assistance Programs: The Current Landscape and the Future</strong></td>
<td>Ayesha Azam</td>
<td>Patient assistance programs are critical for thousands of people who are unable to afford the out-of-pocket costs for their medical and prescription treatment. At the same time, patient assistance programs are facing increased scrutiny. This session will discuss how this scrutiny has affected charitable foundations, the overall impact to the availability of patient assistance, and what specialty pharmacies can do to ensure their patients find financial assistance, so they can start and stay on treatment.</td>
</tr>
<tr>
<td>9:00 AM - 9:30 AM</td>
<td>Margaux 2</td>
<td><strong>Challenges &amp; Opportunities: Onsite Specialty Pharmacy Management for Health Systems</strong></td>
<td>Vaughn Kinosian</td>
<td>This session will discuss the requirements and opportunities for onsite specialty pharmacy for health systems; leveraging third party management based on core specialty pharmacy expertise.</td>
</tr>
<tr>
<td>9:00 AM - 9:30 AM</td>
<td>Mouton 1</td>
<td><strong>Ready for Takeoff: Supporting Your Launch Strategy – Operations, Analytics and Performance</strong></td>
<td>Jeff Krol, Barrett Land and Rob Ririe</td>
<td>Launching a specialty product, whether it’s a company first or an addition to the portfolio, is complex. Manufacturers hone their strategies to support the patient journey, drive positive outcomes and a positive return. And because specialty products are unique from traditional therapies, many fail to adequately prepare their operations to fully support the product and provide visibility to its performance across all channels. Join Pharosity Consulting and Greenwich Biosciences for a discussion on the impact of Market Access strategies on operations, what is needed to gain visibility to contracting and pricing activities, how to measure performance, and where these elements fit into your launch plan.</td>
</tr>
</tbody>
</table>
Thursday, May 2, 2019

9:00 AM - 9:30 AM  
**OMG: Patients Prefer 2 Text: Successfully Adopting the Next Iteration of Patient Communication**  
Speakers: Neng Bing Doh and Alex Vinicombe  
Streamline your process, increase patient adherence and reduce costs while interacting with your patients the way they prefer! See a real life example of how texting your patients can improve your patients experience and your specialty pharmacy operations. Alexander Vinicombe, of PerformSpecialty Pharmacy, and Neng Bing Duh, of Healthcrowd, share their methods and success with text campaigns in the pharmacy environment.

9:45 AM - 10:15 AM  
**Return on Investment (ROI) vs. Value on Investment for (VOI) Outcomes-Based Contracts**  
Speakers: Tom Michalski and Kayse Reitmeyer  
Outcomes based contracts are becoming an expectation rather than a trend. The conversation surrounding these contracts has changed from ROI to VOI. While there is usually no guaranteed return for these types of innovative contracts there is definitely value in supporting and implementing these opportunities. This session will review targeting the best opportunities and attempting to measure the value on investment and most importantly knowing when to walk away from opportunities that are not the right fit for your company.

9:45 AM - 10:15 AM  
**Evolving Employer and Plan Sponsor Expectations to Manage Complex Specialty Products**  
Speaker: David Dross

9:45 AM - 10:15 AM  
**High-Touch and High-Tech Mobile Engagement in the Specialty Pharmacy**  
Speakers: Travis Baughn  
During this session, Dr. Baughn will discuss how combining a high-tech mobile platform with a high-touch engagement model results in an enhanced member experience, and improves clinical outcomes. An effective “High-Touch and High Tech Mobile Engagement” model requires the mobile technology and messaging to be simple, effective, and engaging. This session will discuss this model, and present real-world examples and ideas to support embracing mobile technology in Specialty Pharmacy.
Thursday, May 2, 2019

9:45 AM - 10:15 AM
**USP Chapters 795, 797, 800. Bringing it Together for December 2019**
Speakers: Mala Crossley and Marc Stranz
The intended official date for USP Chapters 795 (Nonsterile Compounding), 797 (Sterile Compounding) and 800 (Hazardous Drugs) is December 2019. This session will review the major changes to these Chapters and provide resources for complying with the requirements.

9:45 AM - 10:15 AM
**Level Up: The Next Stage of Medical Pharmacy Management**
Speaker: Aaron Aten
Are you prepared for rising specialty drug costs and an ever-evolving specialty pipeline? If you’re feeling the heightened sense of urgency to get ahead of the trend and better manage spend, join this session for real-world case studies on how payers are overcoming the cost of care while helping to improve member outcomes. We will examine current utilization, spend, and comprehensive management trends as well as the impact of specialty medications in the pipeline.

10:30 AM - 11:00 AM
**Improving Patient Adherence though AI and the Specialty Pharmacy Channel**
Speakers: Marc Duey and Sriram Krishnan
This session will present a case study showing improvement in patient adherence using artificial intelligence and the specialty pharmacy channel. Patient non-adherence to medications costs biopharma manufacturers millions in lost revenue, with between 40 and 50% of patients not filling. Learn how artificial intelligence can identify patients at risk of not filling/refilling prescriptions. An interactive portal shows specialty pharmacies root cause of the inaction so they can engage patients in order to improve adherence.

10:30 AM - 11:00 AM
**Not in Network: Health System Owned Specialty Pharmacy Perspectives on Obtaining Payor Access**
Speaker: Erin Hendrick
A brief overview on strategies health-systems can employ to improve patient capture and care through being in-network with the commercial payor plans in your catchment area. Additional commentary will be provided by Tim Weber (University of North Carolina) and Ameet Wattamwar (NYU Langone).
Thursday, May 2, 2019

10:30 AM - 11:00 AM
From Months to Minutes – Increasing Speed to Therapy in the Most Challenging Prescribing Workflows
Speakers: Kathy Lewis, Richard Prest and Amanda Robinson

Delays in prescription delivery are costly and dangerous. Aligning medications to coverage, managing controlled substance prescribing, and meeting specialty medications requirements impact speed to therapy. However, standards are breaking down barriers by bringing information into workflows. We are seeing significant improvements in speed and efficiency with advancements in electronic transactions, data intelligence, and workflow automation. Explore how standards and innovations are improving prescriber and pharmacist communications, getting much needed therapies to patients quickly.

10:30 AM - 11:00 AM
Medicines of the Future – Gene Therapy & Precision Medicine
Speakers: Cheryl Allen, Chuck Collins and Paul Urick

Precision Medicine and Genetic Therapies based on each patient’s unique genetic code will test specialty pharmacies, payors, pharmaceutical companies and patients to ensure these crucial and amazingly innovative pharmaceuticals reach patients who need them. This panel will discuss the pipeline, application of genetic and precision medicine, and likely issues surrounding stakeholders.

10:30 AM - 11:00 AM
Crafting a World-Class Patient Experience to Improve Outcomes and Patient Care
Speakers: Champ Burgess and Amy Manning

Have you ever wondered why patients choose one specialty pharmacy over another? Or why some patients leave even if you have provided them with adequate care? In today’s growing market, patients have many specialty pharmacy options to choose from, so how do you stand out from all other organizations? One key way to influence patient behaviors is by intentionally managing the experience you provide them.
Thursday, May 2, 2019

11:15 AM - 11:45 AM

**Current & Future Digital Health Trends Transforming the Practice of Pharmacy**

Speaker: Harry Travis

During this session, Harry will review the definition of various digital technologies - digital health, digital medicine, digital therapeutic, and digital drug, – and he will explore five digital trends that will transform the pharmacy business. These trends include:

1. The Internet of Things is powering a tsunami of digital medication adherence tools;
2. Digital therapeutics are heralding a new way to treat disease;
3. Digital medications will change pharma contracting forever;
4. eCommerce comes to the drug store; and
5. When will Apple make its move.

Join us for a look into the digital health landscape!

11:15 AM - 11:45 AM

**Temperature Control Management for Specialty Products: Pharmacopeial Updates and Best Practices**

Speaker: Rafik Bishara

Storage and transportation of finished drug products are critical activities in an integrated supply chain. These finished drug products include but are not limited to temperature-sensitive small molecules, vaccines, biologics, biotechnological products, radiopharmaceuticals, and drug-device combinations (e.g., drug-eluting stents and auto-injectors). To maintain the quality, every party involved in the storage and transportation of a finished product should have an in-depth understanding of the storage and transportation risks and have the appropriate mitigation strategies in place to control these risks. This session will discuss how the following:

- Good Storage & Distribution Practices - The Future
- Packaging and Storage Requirements - Current Updates
- Storage - Thermal Mapping and Monitoring
- Distribution - Studies and Monitoring

11:15 AM - 11:45 AM

**The Evolving Landscape of Alzheimer’s Disease**

Speaker: Richard Stefanacci

As a greater percentage of the United States population ages compared to previous years, Alzheimer’s disease continues to grow as a national healthcare concern. This session will provide an overview of how the understanding of Alzheimer’s disease is changing, the potential impact of early diagnosis and treatment, and the role that healthcare decision-makers may play in the future.
Thursday, May 2, 2019

11:15 AM - 11:45 AM
**Best Practices in Managing Health System Specialty Pharmacy Quality and Operational Metrics**

Speakers: Mike Gannon, Bob Leinss and Matthew Malachowski

This session will present how two different health systems operated. URAC accredited specialty pharmacies track their program success via key operational and quality metrics. Each will review the metrics they are tracking and provide insights into the best practices learned along the way. They will discuss how specific operations and processes may impact certain quality metrics. Finally, each institution will present the challenges they faced and the solutions implemented to overcome them.

11:30 AM Sign-in • 12:00 PM - 1:30 PM
**CE: Chronic Lymphocytic Leukemia: Evolving Treatment Strategies and the Role of the Specialty Pharmacist in Improving Patient Outcomes**

Speakers: Victoria Brown and Kirollos Hanna

11:30 AM Sign-in and Lunch • 12:00 PM - 1:30 PM
**CE: Examining Treatment Options in Chronic Thromboembolic Pulmonary Hypertension (CTEPH): A Review for Specialty Pharmacists**

Speakers: Rebekah Anguiano and Christopher Ensor

Chronic thromboembolic pulmonary hypertension (CTEPH) is a progressive disease with just a 50% 2-year survival rate from diagnosis to death. Until recently, there were no approved pharmacologic treatments for CTEPH. Traditionally, medications approved for pulmonary arterial hypertension (PAH) are used to treat CTEPH off-label due to the similarity of the pathophysiology of the 2 diseases. Specialty pharmacists have a valuable role to guide appropriate medication use that is both safe and effective. With proper knowledge, pharmacists will be familiar with recent guidelines, best practices, and the range of therapeutic options to optimize patient care while minimizing health care utilization.